A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions
Launched by AMGEN · Dec 8, 2015
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
The objective of this NIS (according to section 4(23) of the German Medicinal Products Act) is the documentation of data on the effectiveness and tolerability of an Apremilast treatment under routine clinical conditions in German patients with plaque psoriasis.
This NIS is intended to reflect the apremilast treatment of patients with plaque psoriasis who have received at least one prior conventional, systemic therapy or, if a contraindication is present, did not receive a systemic therapy so far, and who were diagnosed by their treating physicians to be eligible for an apremilast treatment...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The decision for a therapy with Apremilast was made before enrolment and independent of this study.
- • Patient ≥ 18 years of age
- • Diagnosis of moderate to severe plaque psoriasis
- • Inadequate response or intolerance to a previous systemic treatment, or contraindication for systemic therapies.
- • Written informed consent by the patient for data recording, statistical analysis, filing and forwarding of the data
- Exclusion Criteria:
- • Pregnancy
- • Hypersensitivity to apremilast or any of the excipients of the film-coated tablet
- • Other criteria according to the Summary of product characteristics (SmPC).
About Amgen
Amgen is a leading global biotechnology company dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. With a strong focus on areas such as oncology, cardiovascular disease, and inflammation, Amgen leverages advanced science and technology to address complex medical needs. The company is committed to improving patient outcomes through rigorous clinical trials and robust research initiatives, ensuring the highest standards of safety and efficacy in its products. With a rich pipeline of cutting-edge therapies, Amgen continues to be at the forefront of biopharmaceutical advancements, making a significant impact on healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, Nordrhein Westfalen, Germany
Regensburg, Bayern, Germany
Blaubeuren, Baden Württemberg, Germany
Blaustein, Baden Württemberg, Germany
Esslingen Am Neckar, Baden Württemberg, Germany
Heidelberg, Baden Württemberg, Germany
Karlsruhe, Baden Württemberg, Germany
Karlsruhe, Baden Württemberg, Germany
Karlsruhe, Baden Württemberg, Germany
Karlsruhe, Baden Württemberg, Germany
Langenau, Baden Württemberg, Germany
Mannheim, Baden Württemberg, Germany
Spaichingen, Baden Württemberg, Germany
Erlangen, Bayern, Germany
Freising, Bayern, Germany
Germering, Bayern, Germany
Hersbruck, Bayern, Germany
Krumbach, Bayern, Germany
München, Bayern, Germany
München, Bayern, Germany
München, Bayern, Germany
Würzburg, Bayern, Germany
Falkensee, Brandenburg, Germany
Kleinmachnow, Brandenburg, Germany
Schwedt, Brandenburg, Germany
Eltville, Hessen, Germany
Frankfurt Am Main, Hessen, Germany
Schwalmstadt, Hessen, Germany
Bergen, Mecklenburg Vorpommern, Germany
Neubrandenburg, Mecklenburg Vorpommern, Germany
Braunschweig, Niedersachsen, Germany
Buxtehude, Niedersachsen, Germany
Cloppenburg, Niedersachsen, Germany
Hannover, Niedersachsen, Germany
Hannover, Niedersachsen, Germany
Hildesheim, Niedersachsen, Germany
Holzminden, Niedersachsen, Germany
Lüneburg, Niedersachsen, Germany
Vechta, Niedersachsen, Germany
Winsen, Niedersachsen, Germany
Aachen, Nordrhein Westfalen, Germany
Bielefeld, Nordrhein Westfalen, Germany
Duisburg, Nordrhein Westfalen, Germany
Düren, Nordrhein Westfalen, Germany
Düsseldorf, Nordrhein Westfalen, Germany
Eschweiler, Nordrhein Westfalen, Germany
Euskirchen, Nordrhein Westfalen, Germany
Gelsenkirchen Feldmark, Nordrhein Westfalen, Germany
Gladbeck, Nordrhein Westfalen, Germany
Kleve, Nordrhein Westfalen, Germany
Minden, Nordrhein Westfalen, Germany
Mönchengladbach, Nordrhein Westfalen, Germany
Münster, Nordrhein Westfalen, Germany
Rheinbach, Nordrhein Westfalen, Germany
Stolberg (Rheinland), Nordrhein Westfalen, Germany
Velbert, Nordrhein Westfalen, Germany
Wesel, Nordrhein Westfalen, Germany
Bendorf, Rheinland Pfalz, Germany
Andernach, Rheinland Pfalz, Germany
Koblenz, Rheinland Pfalz, Germany
Mainz, Rheinland Pfalz, Germany
Maxdorf, Rheinland Pfalz, Germany
Neuwied, Rheinland Pfalz, Germany
Prüm, Rheinland Pfalz, Germany
Selters, Rheinland Pfalz, Germany
Simmern, Rheinland Pfalz, Germany
Eilenburg, Sachsen Anhalt, Germany
Magdeburg, Sachsen Anhalt, Germany
Quedlinburg, Sachsen Anhalt, Germany
Weißenfels, Sachsen Anhalt, Germany
Chemnitz, Sachsen, Germany
Dresden, Sachsen, Germany
Dresden, Sachsen, Germany
Dresden, Sachsen, Germany
Dresden, Sachsen, Germany
Leipzig, Sachsen, Germany
Leipzig, Sachsen, Germany
Wurzen, Sachsen, Germany
Kiel, Schleswig Holstein, Germany
Lübeck, Schleswig Holstein, Germany
Neumünster, Schleswig Holstein, Germany
Artern, Thüringen, Germany
Heiligenstadt, Thüringen, Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Bremen, , Germany
Hamburg, , Germany
Hamburg, , Germany
Hamburg, , Germany
Königs Wusterhausen, , Germany
Vilshofen, , Germany
Blaubeuren, , Germany
Blaustein, , Germany
Esslingen Am Neckar, , Germany
Heidelberg, , Germany
Karlsruhe, , Germany
Karlsruhe, , Germany
Karlsruhe, , Germany
Karlsruhe, , Germany
Langenau, , Germany
Mannheim, , Germany
Spaichingen, , Germany
Artern, , Germany
Heiligenstadt, , Germany
Patients applied
Trial Officials
MD
Study Director
Amgen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials